含贝达喹啉、普托马尼和利奈唑胺的新型短程方案治疗耐利福平结核的安全性与耐受性:个体患者数据Meta分析
该个体患者数据Meta分析纳入2010至2021年间3项临床试验、8种含BPaL方案、共591例耐多药/耐利福平结核患者,评估利奈唑胺的安全性与耐受性。结果显示,随机分配至利奈唑胺日剂量1200 mg组中195例有68例(35%)发生3-4级不良事件,而含利奈唑胺600 mg的BPaL方案组396例中89例(22%)发生。含BPaL方案在利奈唑胺日剂量600 mg时耐受性相对良好。
要点
- 利奈唑胺日剂量1200 mg组3-4级不良事件发生率为35%(68/195),高于600 mg组的22%(89/396)。
- 累积利奈唑胺剂量较高的组别不良事件更频繁。
- 含BPaL方案在利奈唑胺日剂量600 mg时耐受性相对良好。
核心结论
- 含BPaL方案在利奈唑胺日剂量为600 mg时耐受性相对良好,这些新型方案有望改善耐多药/耐利福平结核治疗的耐受性。
研究设计与样本
- 研究为回顾与Meta分析,纳入2010至2021年间评估含BPaL方案治疗耐多药/耐利福平结核的临床试验的已发表和未发表数据,获取个体患者数据。
- 共纳入3项临床试验、8种含BPaL方案、591例参与者。
- 对每种含BPaL方案评估治疗相关不良事件的频率与严重程度,并与接受最低累积利奈唑胺暴露的患者比较不良事件风险差。
主要发现
- 随机分配至利奈唑胺日剂量1200 mg组的195例患者中,68例(35%)发生3-4级不良事件。
- 接受含利奈唑胺600 mg的BPaL方案组的396例患者中,89例(22%)发生3-4级不良事件。
- 随机分配至较高累积利奈唑胺剂量组的不良事件更频繁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without a fourth drug, have been shown to be as or more effective than the established longer regimens for the treatment of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB). We aimed to evaluate the safety and tolerability of linezolid in BPaL-containing regimens for the treatment of MDR/RR-TB among recently completed clinical trials. METHODS: A review and meta-analysis was undertaken including published and unpublished data from clinical trials, conducted between 2010 and 2021, that evaluated regimens containing BPaL for the treatment of MDR/RR-TB. Individual patient data were obtained. For each BPaL-containing regimen, we evaluated the frequency and severity of treatment-related adverse events. The risk difference of adverse events for each regimen was calculated, in comparison to patients assigned to receiving the lowest cumulative exposure of linezolid. RESULTS: Data from 3 clinical trials investigating 8 unique BPaL-containing regimens were included, comprising a total of 591 participants. Adverse events were more frequent in groups randomized to a higher cumulative linezolid dose. Among patients who were randomized to a daily dose of 1200 mg linezolid, 68 of 195 (35%) experienced a grade 3-4 adverse event versus 89 of 396 (22%) patients receiving BPaL-containing regimens containing 600 mg linezolid. CONCLUSIONS: Regimens containing BPaL were relatively well tolerated when they included a daily linezolid dose of 600 mg. These novel regimens promise to improve the tolerability of treatment for MDR/RR-TB.
引用
- Hasan T, Medcalf E, Nyang'wa BT, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Clin Infect Dis. 2024. PMID: 37874021. doi:10.1093/cid/ciad653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。